DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» MOPP (chemotherapy)
MOPP (chemotherapy)
Hodgkin Lymphoma Treatment Regimens
Bendamustine in Combination with Gemcitabine and Vinorelbine Is An
Dacarbazine for Injection, USP
Anti Cancer Chemotherapy
Appendix C Medication Tables
Effective for Cases Diagnosed January 1, 2016 and Later
Principles of Chemotherapy and Other Agents
Acronyms for Oncology Regimens
The Cancer and Leukemia Group B Lymphoma Committee Bruce D
Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-By-Layer Nanoparticle Erik C
Role of Chemotherapy in Hodgkin's Lymphoma
NCCN Guidelines for Hodgkin Lymphoma V.1.2020 – Web Teleconference 07/26/19
Chemotherapy Drugs
Drug Metabolism Group
Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations
Supplementary Table S4: Global List of Studied Associations for Chl Prognosis and Treatment Response
Management of Advanced Hodgkin's Lymphoma
United States Patent $835 a 88: As: Inhibitor 1-((R)-3-(4-Amino-3-(4
Top View
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Gary J
CHOP Chemotherapy for the Treatment of Canine Multicentric Tcell Lymphoma
Hybrid Drugs—A Strategy for Overcoming Anticancer Drug Resistance?
Forodesine in the Treatment of Relapsed/Refractory Peripheral T-Cell Lymphoma: an Evidence-Based Review
DRUG NAME Toxicities: Acute: Delayed: Subclass Enzyme/Antigen
Supplementary Table 1. Summary of FDA-Approved Anticancer Cytotoxic Drugs at May 2019
Hodgkin Lymphoma—Stage III and IV
Chemical Protocol Review
Do Affluent Societies Have the Only Options for the Best Therapy?
ICD-10-CM TABLE of DRUGS and CHEMICALS 2020
Hodgkin Lymphoma: Faculty Advancing Beyond Standard Volker Diehl, MD Professor of Medicine University of Cologne Management Cologne, Germany
©Ferrata Storti Foundation
DRUG NAME Toxicities: Acute: Delayed: Subclass Mechanism of Action
Bendamustine Pharmaceutical Compositions for Lyophilisation
Rescue Protocols for Canine Lymphoma
Antineoplastics II
[email protected]
Page 1 of 35
Cardiopulmonary Toxicity of Different Chemoradiotherapy Combined Regimens for Hodgkin’S Disease
©Ferrata Storti Foundation
Study Protocol
MUSTARGEN® (MECHLORETHAMINE Hcl for INJECTION)
Title. Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-By-Layer Nanoparticle
Drug Metabolism and Disposition Uptake Carriers and Oncology Drug
Chemotherapy Strategies to Improve the Control of Hodgkin's Disease: the Richard and Hinda Rosenthal Foundation Award Lecture1
Download PDF to Print
The Chemotherapy of Lymphomas: Looking Back, Moving Forward—The Richard and Hinda Rosenthal Foundation Award Lecture1
Brentuximab Vedotin in Combination with Bendamustine for Patients with Relapsed/Refractory Hodgkin Lymphoma After Front-Line Therapy
NCI Congressional Justification FY 2005
Chlvpp Alternating with Pabloe Is Superior to Pabloe
Open Full Page
Will It Be Another 20 Years Before Hodgkin Lymphoma Patients Benefit from BEACOPP Therapy? Volker Diehl and Andreas Engert
Program Slides
Antineoplastic Drugs